3D Medicines Inc. (HKG:1244)
Hong Kong · Delayed Price · Currency is HKD 7.63
-0.30 (-3.78%)
Sep 5, 2025, 4:08 PM HKT
3D Medicines Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 448.39 | 445.65 | 634.95 | 567.39 | 60.26 | - | |
Revenue Growth (YoY) | -8.27% | -29.81% | 11.91% | 841.57% | - | - |
Cost of Revenue | 74.71 | 73.91 | 110.94 | 102.18 | 11.43 | - |
Gross Profit | 373.68 | 371.74 | 524.01 | 465.21 | 48.83 | - |
Selling, General & Admin | 301.89 | 314.19 | 595.89 | 500.49 | 193.79 | 40.53 |
Research & Development | 178.55 | 180.72 | 425.5 | 350.86 | 371.16 | 263.97 |
Other Operating Expenses | -9.7 | - | - | - | 4.28 | - |
Operating Expenses | 471 | 495.17 | 1,021 | 851.38 | 569.36 | 304.5 |
Operating Income | -97.33 | -123.43 | -497.25 | -386.17 | -520.53 | -304.5 |
Interest Expense | -7.74 | -9.5 | -7.77 | -3.11 | -1.53 | -8.06 |
Interest & Investment Income | 23.4 | 25.76 | 19.47 | 9.12 | 5.93 | 1.77 |
Currency Exchange Gain (Loss) | 1.88 | 8.98 | -2.55 | 34.86 | -3.7 | -5.93 |
Other Non Operating Income (Expenses) | -96.35 | -99.88 | -82.45 | -705.74 | -941.21 | -318.66 |
EBT Excluding Unusual Items | -176.13 | -198.08 | -570.56 | -1,051 | -1,461 | -635.38 |
Gain (Loss) on Sale of Investments | -0.37 | -0.89 | 8.09 | -0.99 | 0.18 | - |
Gain (Loss) on Sale of Assets | - | - | - | - | -0.96 | -0 |
Asset Writedown | -4.07 | -4.07 | - | - | - | - |
Other Unusual Items | 2.57 | 3.66 | - | - | - | - |
Pretax Income | -177.99 | -199.38 | -562.47 | -1,052 | -1,462 | -635.38 |
Income Tax Expense | -0.06 | - | 0.06 | - | - | - |
Earnings From Continuing Operations | -177.94 | -199.38 | -562.52 | -1,052 | -1,462 | -635.38 |
Minority Interest in Earnings | 9.43 | 16.72 | 37.82 | 27.68 | 27.73 | - |
Net Income | -168.5 | -182.66 | -524.7 | -1,024 | -1,434 | -635.38 |
Net Income to Common | -168.5 | -182.66 | -524.7 | -1,024 | -1,434 | -635.38 |
Shares Outstanding (Basic) | 245 | 245 | 228 | 45 | 39 | 46 |
Shares Outstanding (Diluted) | 245 | 245 | 228 | 45 | 39 | 46 |
Shares Change (YoY) | 2.63% | 7.22% | 402.26% | 16.48% | -14.36% | - |
EPS (Basic) | -0.69 | -0.75 | -2.30 | -22.52 | -36.72 | -13.93 |
EPS (Diluted) | -0.69 | -0.75 | -2.30 | -22.52 | -36.72 | -13.93 |
Free Cash Flow | - | -255.94 | -150.74 | -332.76 | -420.95 | -289.48 |
Free Cash Flow Per Share | - | -1.04 | -0.66 | -7.32 | -10.78 | -6.35 |
Gross Margin | 83.34% | 83.41% | 82.53% | 81.99% | 81.03% | - |
Operating Margin | -21.71% | -27.70% | -78.31% | -68.06% | -863.81% | - |
Profit Margin | -37.58% | -40.99% | -82.64% | -180.54% | -2379.84% | - |
Free Cash Flow Margin | - | -57.43% | -23.74% | -58.65% | -698.56% | - |
EBITDA | -88.3 | -114.53 | -489.39 | -378.3 | -516.78 | -303.35 |
EBITDA Margin | -19.69% | -25.70% | -77.08% | -66.67% | - | - |
D&A For EBITDA | 9.02 | 8.91 | 7.86 | 7.87 | 3.75 | 1.15 |
EBIT | -97.33 | -123.43 | -497.25 | -386.17 | -520.53 | -304.5 |
EBIT Margin | -21.70% | -27.70% | -78.31% | -68.06% | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.